Xu He, DO
Internal Medicine · Redlands, CANPI 1568773448
Payments from drug & device makers
Across 1,805 payments — averaging $194.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$79K
- Biohaven Pharmaceuticals, Inc.$57K
- Pfizer$39K
- Biohaven Pharmaceutical Holding Company Ltd.$31K
- Idorsia Pharmaceuticals US Inc$24K
- Phathom Pharmaceuticals, Inc.$23K
- plus $97K from 54 others
What the payments were for
- Consulting fees$21,6616%
- Speaking & faculty fees$240,62769%
- Travel & lodging$43,96513%
- Food & beverage$44,73913%
- Education$1360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$105,759
- REXULTI$75,059
- QUVIVIQ$22,975
- VOQUEZNA$21,769
- AREXVY$17,112
- CeQur Simplicity$16,612
- ZAVZPRET$15,345
- ZYPITAMAG (pitavastatin)$9,500
- Kerendia$6,362
- ImmunoCAP$4,500
- Reltone 200 Mg$3,625
- GLYCATE$3,625
- Reltone 400 Mg$3,625
- KRYSTEXXA$1,944
- FARXIGA$1,319
- JARDIANCE$721
- AIRSUPRA$616
- Korlym$587
- FREESTYLE LIBRE 3$404
- Inpefa$368
How this compares
$351,128 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 222 | $177,182 |
| OzempicSemaglutide | 148 | $175,437 |
| EliquisApixaban | 175 | $139,655 |
| RybelsusSemaglutide | 71 | $86,005 |
| FarxigaDapagliflozin Propanediol | 89 | $60,400 |
| KerendiaFinerenone | 78 | $59,308 |
| TrulicityDulaglutide | 54 | $55,430 |
| Nurtec OdtRimegepant Sulfate | 35 | $47,239 |
| XareltoRivaroxaban | 59 | $45,264 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 43 | $42,625 |
| MounjaroTirzepatide | 30 | $30,882 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $27,281 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $20,900 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $20,292 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 36 | $19,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,238 | $261,442219 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Spiriva Respimat | $3,113 | $220,367283 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $39,430 | $191,397224 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $540 | $86,31384 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $4,800 | $81,300117 claims |
| BayerKerendia | $7,169 | $59,30878 claims |
| Johnson & JohnsonXarelto | $645 | $45,26459 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $18,773 | $43,66963 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,846 | $42,62543 claims |
| Cequr CorporationCequr Simplicity | $16,612 | $19,58836 claims |
| AbbVieLinzess | $2,321 | $18,37232 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $79,435 | $16,32113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Redlands
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.